NightHawk Biosciences Inc (NHWK)

[dia76ca]

The most exciting part of the January 31 Noble conference was the Question Time at the end. CEO Wolf was asked about companies that had developed checkpoint inhibitors and their attitude to HTBX's combination trial. Wolf mentioned 3 companies...BMS, Merck and AZN. Wolf said that their attitude was very favourable and in regard to combining with us "...they know what we are doing. They are waiting for the results of this trial."

There has been a lot of discussion about BMS and Merck being interested...but this is the first I can recall of any reference to AZN. The reason I mention this is that Dr. Hutchins had contacts with AZN while he was at PPHM. I am looking at what Dr. Hutchins brings to the company and I am wondering about his contacts with PPHM and AZN. When they talk about in-licencing (2017 targeted goal #5) I wonder about PPHM's Bavituximab and betabodies and AZN's Durvalumab.

The best result for shareholders is that BMS, Merck and AZN are ALL interested. Bidding for a partnership or a buyout would be nice!